You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

5178 Results
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
Document
Dec 1969
In October 2024, the Ontario Breast Screening Program lowered the starting age for screening from age 50 to age 40.This page provides breast cancer...
En octobre 2024, le Programme ontarien de dépistage du cancer du sein a abaissé l’âge de début du dépistage de 50 à 40 ans. Cette page fournit de l’...
Statistical Reports
Ontario Cancer Statistics 2024 is the fifth in a series of reports that provide comprehensive information on the burden of cancer in Ontario....
Dec 1969
Statistical Reports
Les statistiques sur le cancer en Ontario 2024 représentent le cinquième d'une série de rapports qui fournissent des informations approfondies sur l'...
Dec 1969
Drug
Other Name(s): Orgovyx®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 1969
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    relugolix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
relugolix
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Regimen
Cancer Type:
Endocrine, 
Pancreatic Neuroendocrine, 
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    Belzutifan – For the treatment of adult patients with von Hippel-Lindau (vHL) disease, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
belzutifan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Guidelines and Advice
Status: Current
ID: GL 1-14
Version: 3
Oct 2019

Pages